Stay updated with breaking news from Kartik manne. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
To block infection from HIV, a successful vaccine will require a combination of ingredients, including at least three antibody targets and a substance that boosts immune responses.
To block infection from HIV, a successful vaccine will require a combination of ingredients, including at least three antibody targets and a substance that boos
CHAPEL HILL & DURHAM - A research collaboration between scientists at Duke University and the University of North Carolina at Chapel Hill has identified and
Duke study reveals mechanisms of increased infectivity, antibody resistance of SARS-CoV-2 variants eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
E-Mail DURHAM, N.C. - A newly identified group of antibodies that binds to a coating of sugars on the outer shell of HIV is effective in neutralizing the virus and points to a novel vaccine approach that could also potentially be used against SARS-CoV-2 and fungal pathogens, researchers at the Duke Human Vaccine Institute report. In a study appearing online May 20 in the journal Cell, the researchers describe an immune cell found in both monkeys and humans that produces a unique type of anti-glycan antibody. This newly described antibody has the ability to attach to the outer layer of HIV at a patch of glycans -- the chain-like structures of sugars that are on the surfaces of cells, including the outer shells of viruses.
Share A potential new vaccine developed by members of the Duke Human Vaccine Institute has proven effective in protecting monkeys and mice from a variety of coronavirus infections — including SARS-CoV-2 as well as the original SARS-CoV-1 and related bat coronaviruses that could potentially cause the next pandemic. The new vaccine, called a pan-coronavirus vaccine, triggers neutralizing antibodies via a nanoparticle. The nanoparticle is composed of the coronavirus part that allows it to bind to the body’s cell receptors, and is formulated with a chemical booster called an adjuvant. Success in primates is highly relevant to humans. The findings appear Monday, May 10 in the journal Nature.
by Sarah Avery — May 10, 2021 . DURHAM – A potential new vaccine developed by members of the Duke Human Vaccine Institute has proven effective in protecting monkeys and mice from a variety of coronavirus infections – including SARS-CoV-2 as well as the original SARS-CoV-1 and related bat coronaviruses that could potentially cause the next pandemic. The new vaccine, called a pan-coronavirus vaccine, triggers neutralizing antibodies via a nanoparticle. The nanoparticle is composed of the coronavirus part that allows it to bind to the body’s cell receptors, and is formulated with a chemical booster called an adjuvant. Success in primates is highly relevant to humans.
E-Mail DURHAM, N.C. - A potential new vaccine developed by members of the Duke Human Vaccine Institute has proven effective in protecting monkeys and mice from a variety of coronavirus infections -- including SARS-CoV-2 as well as the original SARS-CoV-1 and related bat coronaviruses that could potentially cause the next pandemic. The new vaccine, called a pan-coronavirus vaccine, triggers neutralizing antibodies via a nanoparticle. The nanoparticle is composed of the coronavirus part that allows it to bind to the body's cell receptors and is formulated with a chemical booster called an adjuvant. Success in primates is highly relevant to humans.